Operating Income (Loss) in USD of Ambrx Biopharma Cayman, Inc. from 2019 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2019 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Operating Income (Loss) for the quarter ending 30 Jun 2023 was -$19,170,000.000, a 33.4% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2022 was -$76,401,000.000, a 18.6% decline from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2021 was -$64,424,000.000, a 391% decline from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2020 was -$13,115,000.000, a 41.6% increase from 2019.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$19,170,000 +$9,611,000 +33.4% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 -$16,032,000 +$4,094,000 +20.3% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023
Q2 2022 -$28,781,000 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 -$20,126,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023

Ambrx Biopharma Cayman, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$76,401,000 -$11,977,000 -18.6% 01 Jan 2022 31 Dec 2022 10-K 30 Mar 2023
2021 -$64,424,000 -$51,309,000 -3.9% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 -$13,115,000 +$9,357,000 +41.6% 01 Jan 2020 31 Dec 2020 20-F 26 Apr 2022
2019 -$22,472,000 01 Jan 2019 31 Dec 2019 20-F 26 Apr 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.